deferiprone has been researched along with Disease Models, Animal in 42 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Since depression severity has been reported to correlate with brain iron levels, the present study aimed to characterise the potential antidepressant properties of the iron chelator deferiprone." | 8.12 | Novel Antidepressant-Like Properties of the Iron Chelator Deferiprone in a Mouse Model of Depression. ( Aitken, C; Bush, AI; Hale, MW; Hannan, AJ; Li, S; Mawal, CH; Opazo, CM; Payet, JM; Renoir, T; Tran, H; Uzungil, V; Wilson, C, 2022) |
| " The oral iron chelator deferiprone (DFP) is protective against retinal degenerations associated with oxidative stress." | 7.96 | Oral administration of the iron chelator deferiprone protects against loss of retinal ganglion cells in a mouse model of glaucoma. ( Bargoud, AR; Cui, QN; Dunaief, JL; Ross, AG; Song, Y, 2020) |
| "Herein, the efficacy of free deferiprone (DFP) and DFP-loaded starch/polyethylene glycol/polyacrylic acid (St/PEG/PAAc) nanogel [Nano-DFP] in modulating the biochemical changes induced by glycerol model of rhabdomyolysis (RBD) in male rats was investigated." | 7.96 | Effectiveness of deferiprone-loaded nanocarrier in experimentally induced rhabdomyolysis: A dose-comparison study. ( Deghiedy, NM; El-Ghazaly, MA; El-Hazek, RM; El-Sabbagh, WA; Rashed, ER; Rashed, RR, 2020) |
| " Our aim is to determine the antiinflammatory activity of deferiprone, an oral iron chelator, in experimental colitis and gastritis." | 7.70 | Deferiprone, an oral iron chelator, ameliorates experimental colitis and gastric ulceration in rats. ( Ablin, J; Karmeli, F; Okon, E; Rachmilewitz, D; Shalev, O, 1999) |
| "Iron overload was induced in male ICR mice by injection of iron sucrose (10mg/kg/day) for eight weeks." | 5.43 | Tetrahydrocurcumin in combination with deferiprone attenuates hypertension, vascular dysfunction, baroreflex dysfunction, and oxidative stress in iron-overloaded mice. ( Donpunha, W; Kukongviriyapan, U; Kukongviriyapan, V; Pakdeechote, P; Sangartit, W; Shibahara, S, 2016) |
| "Oral deferiprone holds promise in the treatment of iron poisoning in humans." | 5.31 | The efficacy of oral deferiprone in acute iron poisoning. ( Bentur, Y; Berkovitch, M; Klein, J; Koren, G; Livne, A; Lushkov, G; Segal, M; Talmor, C, 2000) |
| " Since depression severity has been reported to correlate with brain iron levels, the present study aimed to characterise the potential antidepressant properties of the iron chelator deferiprone." | 4.12 | Novel Antidepressant-Like Properties of the Iron Chelator Deferiprone in a Mouse Model of Depression. ( Aitken, C; Bush, AI; Hale, MW; Hannan, AJ; Li, S; Mawal, CH; Opazo, CM; Payet, JM; Renoir, T; Tran, H; Uzungil, V; Wilson, C, 2022) |
| " The oral iron chelator deferiprone (DFP) is protective against retinal degenerations associated with oxidative stress." | 3.96 | Oral administration of the iron chelator deferiprone protects against loss of retinal ganglion cells in a mouse model of glaucoma. ( Bargoud, AR; Cui, QN; Dunaief, JL; Ross, AG; Song, Y, 2020) |
| "Herein, the efficacy of free deferiprone (DFP) and DFP-loaded starch/polyethylene glycol/polyacrylic acid (St/PEG/PAAc) nanogel [Nano-DFP] in modulating the biochemical changes induced by glycerol model of rhabdomyolysis (RBD) in male rats was investigated." | 3.96 | Effectiveness of deferiprone-loaded nanocarrier in experimentally induced rhabdomyolysis: A dose-comparison study. ( Deghiedy, NM; El-Ghazaly, MA; El-Hazek, RM; El-Sabbagh, WA; Rashed, ER; Rashed, RR, 2020) |
| " Treatment of NZB/W mice with the iron chelator deferiprone significantly delayed the onset of albuminuria and reduced blood urea nitrogen concentrations." | 3.85 | Renal iron accumulation occurs in lupus nephritis and iron chelation delays the onset of albuminuria. ( Boesen, EI; Bonnemaison, ML; Brusnahan, SK; Fan, W; Garrison, JC; Marks, ES; Zhang, W, 2017) |
| "Nephrogenic systemic fibrosis is associated with gadolinium contrast exposure in patients with reduced kidney function and carries high morbidity and mortality." | 3.81 | Evidence Suggesting a Role of Iron in a Mouse Model of Nephrogenic Systemic Fibrosis. ( Bose, C; Hall, KA; Hiatt, KM; Karaduta, O; Megyesi, JK; Shah, SV; Swaminathan, S, 2015) |
| "Although the beneficial effects of deferoxamine (DFO) on iron-associated morbidity and mortality are well documented, the role of deferiprone (L1) in the management of transfusional iron overload is controversial." | 3.71 | The iron-loaded gerbil model revisited: effects of deferoxamine and deferiprone treatment. ( Hershko, C; Huerta, M; Konijn, AM; Link, G; Reinus, C; Rosenmann, E, 2002) |
| " Our aim is to determine the antiinflammatory activity of deferiprone, an oral iron chelator, in experimental colitis and gastritis." | 3.70 | Deferiprone, an oral iron chelator, ameliorates experimental colitis and gastric ulceration in rats. ( Ablin, J; Karmeli, F; Okon, E; Rachmilewitz, D; Shalev, O, 1999) |
| "The pathophysiological role of iron in Parkinson's disease (PD) was assessed by a chelation strategy aimed at reducing oxidative damage associated with regional iron deposition without affecting circulating metals." | 2.79 | Targeting chelatable iron as a therapeutic modality in Parkinson's disease. ( Auger, F; Bordet, R; Cabantchik, ZI; Corvol, JC; Defebvre, L; Destée, A; Devedjian, JC; Devos, D; Duhamel, A; Dujardin, K; Firdaus, W; Garçon, G; Grolez, G; Hopes, L; Jissendi, P; Jonneaux, A; Kluza, J; Laloux, C; Leist, M; Marchetti, P; Moreau, C; Petrault, M; Pöltl, D; Ravasi, L; Rose, C; Rouaix, N; Ryckewaert, G; Sablonnière, B; Strubi-Vuillaume, I; Zahr, N, 2014) |
| " Moreover, this therapeutic combination of agents is safe and does not weaken the healing of the sutured enterotomy site." | 1.62 | Prevention of adhesions post-abdominal surgery: Assessing the safety and efficacy of Chitogel with Deferiprone in a rat model. ( Bassiouni, A; Bennett, C; Cooksley, C; Finnie, J; Jones, CF; Maddern, G; Moratti, S; Psaltis, AJ; Quarrington, RD; Trochsler, M; Vediappan, RS; Vreugde, S; Wormald, PJ, 2021) |
| "Intramyocardial hemorrhage is an independent predictor of adverse outcomes in ST-segment elevation myocardial infarction (STEMI)." | 1.56 | Action of iron chelator on intramyocardial hemorrhage and cardiac remodeling following acute myocardial infarction. ( Barry, J; Behrouzi, B; Connelly, J; Ghugre, NR; Manca, D; Qi, X; Rabadia, V; Spino, M; Strauss, BH; Weyers, JJ; Wood, JC; Wright, GA, 2020) |
| "Treatment with deferiprone of UROS-deficient erythroid cell lines and peripheral blood CD34+-derived erythroid cultures from a patient with CEP inhibited iron-dependent protein ALAS2 and iron-responsive element-binding protein 2 expression and reduced porphyrin production." | 1.56 | Iron chelation rescues hemolytic anemia and skin photosensitivity in congenital erythropoietic porphyria. ( Bedel, A; Blouin, JM; Costet, P; Daher, R; Ged, C; Gouya, L; Karim, Z; Lalanne, M; Lamrissi-Garcia, I; Moreau-Gaudry, F; Morice-Picard, F; Puy, H; Richard, E, 2020) |
| "Brain iron overload is chronic and slow progressing and plays an important role in the pathogenesis of neurodegenerative disorders." | 1.51 | MRI imaging and histopathological study of brain iron overload of β-thalassemic mice. ( Fucharoen, S; Huaijantug, S; Morales, NP; Svasti, S; Teerapan, W; Yatmark, P, 2019) |
| "Deferiprone (DFP) is an oral iron chelator used for the treatment of systemic iron overload disorders, and has recently been tested for Parkinson's disease." | 1.48 | Iron chelator deferiprone rescues memory deficits, hippocampal BDNF levels and antioxidant defenses in an experimental model of memory impairment. ( Alcalde, LA; Bogo, MR; de Freitas Crivelaro, PC; de Freitas, BS; Dornelles, VC; Gus, H; Kist, LW; Machado, GDB; Monteiro, RT; Schröder, N, 2018) |
| "Iron overload was induced in male ICR mice by injection of iron sucrose (10mg/kg/day) for eight weeks." | 1.43 | Tetrahydrocurcumin in combination with deferiprone attenuates hypertension, vascular dysfunction, baroreflex dysfunction, and oxidative stress in iron-overloaded mice. ( Donpunha, W; Kukongviriyapan, U; Kukongviriyapan, V; Pakdeechote, P; Sangartit, W; Shibahara, S, 2016) |
| "Porphyria cutanea tarda is a liver disease characterized by elevated hepatic iron and excessive production of uroporphyrin (URO)." | 1.34 | Effect of an oral iron chelator or iron-deficient diets on uroporphyria in a murine model of porphyria cutanea tarda. ( Balestra, D; Gorman, N; Jacobs, JM; Jacobs, NJ; Sinclair, JF; Sinclair, PR; Szakacs, JG; Trask, HS; Zaharia, A, 2007) |
| "Deferiprone-treated hearts had greater mass (16." | 1.33 | Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. ( Aguilar, MI; Gonzalez, I; Moats, R; Nelson, M; Nick, H; Otto-Duessel, M; Shimada, H; Wood, JC, 2006) |
| "Oral deferiprone holds promise in the treatment of iron poisoning in humans." | 1.31 | The efficacy of oral deferiprone in acute iron poisoning. ( Bentur, Y; Berkovitch, M; Klein, J; Koren, G; Livne, A; Lushkov, G; Segal, M; Talmor, C, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (4.76) | 18.2507 |
| 2000's | 6 (14.29) | 29.6817 |
| 2010's | 22 (52.38) | 24.3611 |
| 2020's | 12 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, X | 1 |
| Guo, J | 1 |
| Lv, Y | 1 |
| Yao, C | 1 |
| Zhang, C | 1 |
| Mi, Z | 1 |
| Shi, Y | 1 |
| Gu, J | 1 |
| Zhou, T | 1 |
| Bai, R | 1 |
| Xie, Y | 1 |
| Shukla, JJ | 1 |
| Stefanova, N | 1 |
| Bush, AI | 4 |
| McColl, G | 1 |
| Finkelstein, DI | 2 |
| McAllum, EJ | 1 |
| Uzungil, V | 1 |
| Tran, H | 1 |
| Aitken, C | 1 |
| Wilson, C | 1 |
| Opazo, CM | 1 |
| Li, S | 1 |
| Payet, JM | 1 |
| Mawal, CH | 1 |
| Hale, MW | 1 |
| Hannan, AJ | 1 |
| Renoir, T | 1 |
| Yao, F | 1 |
| Peng, J | 1 |
| Zhang, E | 1 |
| Ji, D | 1 |
| Gao, Z | 1 |
| Tang, Y | 1 |
| Yao, X | 1 |
| Xia, X | 1 |
| Sripetchwandee, J | 1 |
| Khamseekaew, J | 1 |
| Svasti, S | 3 |
| Srichairatanakool, S | 2 |
| Fucharoen, S | 3 |
| Chattipakorn, N | 1 |
| Chattipakorn, SC | 1 |
| Cui, QN | 1 |
| Bargoud, AR | 1 |
| Ross, AG | 1 |
| Song, Y | 3 |
| Dunaief, JL | 3 |
| Behrouzi, B | 1 |
| Weyers, JJ | 1 |
| Qi, X | 1 |
| Barry, J | 1 |
| Rabadia, V | 1 |
| Manca, D | 1 |
| Connelly, J | 3 |
| Spino, M | 3 |
| Wood, JC | 2 |
| Strauss, BH | 1 |
| Wright, GA | 1 |
| Ghugre, NR | 1 |
| Rosignol, I | 1 |
| Villarejo-Zori, B | 1 |
| Teresak, P | 1 |
| Sierra-Filardi, E | 1 |
| Pereiro, X | 1 |
| Rodríguez-Muela, N | 1 |
| Vecino, E | 1 |
| Vieira, HLA | 1 |
| Bell, K | 1 |
| Boya, P | 1 |
| Rashed, RR | 1 |
| Deghiedy, NM | 1 |
| El-Hazek, RM | 1 |
| El-Sabbagh, WA | 1 |
| Rashed, ER | 1 |
| El-Ghazaly, MA | 1 |
| Blouin, JM | 1 |
| Ged, C | 1 |
| Lalanne, M | 1 |
| Lamrissi-Garcia, I | 1 |
| Morice-Picard, F | 1 |
| Costet, P | 1 |
| Daher, R | 1 |
| Moreau-Gaudry, F | 1 |
| Bedel, A | 1 |
| Puy, H | 1 |
| Gouya, L | 1 |
| Karim, Z | 1 |
| Richard, E | 1 |
| Rao, SS | 1 |
| Portbury, SD | 1 |
| Lago, L | 1 |
| Adlard, PA | 2 |
| Vediappan, RS | 1 |
| Bennett, C | 1 |
| Cooksley, C | 1 |
| Finnie, J | 1 |
| Trochsler, M | 1 |
| Quarrington, RD | 1 |
| Jones, CF | 1 |
| Bassiouni, A | 1 |
| Moratti, S | 1 |
| Psaltis, AJ | 1 |
| Maddern, G | 1 |
| Vreugde, S | 2 |
| Wormald, PJ | 2 |
| Vadolas, J | 1 |
| Ng, GZ | 1 |
| Kysenius, K | 1 |
| Crouch, PJ | 1 |
| Dames, S | 1 |
| Eisermann, M | 1 |
| Nualkaew, T | 1 |
| Vilcassim, S | 1 |
| Schaeper, U | 1 |
| Grigoriadis, G | 1 |
| Richter, K | 1 |
| Thomas, N | 1 |
| Zhang, G | 1 |
| Prestidge, CA | 1 |
| Coenye, T | 1 |
| Marks, ES | 1 |
| Bonnemaison, ML | 1 |
| Brusnahan, SK | 1 |
| Zhang, W | 1 |
| Fan, W | 1 |
| Garrison, JC | 1 |
| Boesen, EI | 1 |
| Moreau, C | 2 |
| Danel, V | 1 |
| Devedjian, JC | 2 |
| Grolez, G | 2 |
| Timmerman, K | 1 |
| Laloux, C | 2 |
| Petrault, M | 2 |
| Gouel, F | 1 |
| Jonneaux, A | 2 |
| Dutheil, M | 1 |
| Lachaud, C | 1 |
| Lopes, R | 1 |
| Kuchcinski, G | 1 |
| Auger, F | 2 |
| Kyheng, M | 1 |
| Duhamel, A | 2 |
| Pérez, T | 1 |
| Pradat, PF | 1 |
| Blasco, H | 1 |
| Veyrat-Durebex, C | 1 |
| Corcia, P | 1 |
| Oeckl, P | 1 |
| Otto, M | 1 |
| Dupuis, L | 1 |
| Garçon, G | 2 |
| Defebvre, L | 2 |
| Cabantchik, ZI | 2 |
| Duce, J | 1 |
| Bordet, R | 2 |
| Devos, D | 2 |
| Sun, Y | 1 |
| Pham, AN | 1 |
| Waite, TD | 1 |
| Savage, KA | 1 |
| Parquet, MC | 1 |
| Allan, DS | 1 |
| Davidson, RJ | 1 |
| Holbein, BE | 1 |
| Lilly, EA | 1 |
| Fidel, PL | 1 |
| Alcalde, LA | 1 |
| de Freitas, BS | 1 |
| Machado, GDB | 1 |
| de Freitas Crivelaro, PC | 1 |
| Dornelles, VC | 1 |
| Gus, H | 1 |
| Monteiro, RT | 1 |
| Kist, LW | 1 |
| Bogo, MR | 1 |
| Schröder, N | 1 |
| Yatmark, P | 2 |
| Huaijantug, S | 1 |
| Teerapan, W | 1 |
| Morales, NP | 2 |
| Ayton, S | 1 |
| Lei, P | 1 |
| Duce, JA | 1 |
| Wong, BX | 1 |
| Sedjahtera, A | 1 |
| Soriano, S | 1 |
| Llorens, JV | 1 |
| Blanco-Sobero, L | 1 |
| Gutiérrez, L | 1 |
| Calap-Quintana, P | 1 |
| Morales, MP | 1 |
| Moltó, MD | 1 |
| Martínez-Sebastián, MJ | 1 |
| Iranmanesh, M | 1 |
| Fatemi, SJ | 1 |
| Golbafan, MR | 1 |
| Balooch, FD | 1 |
| Kluza, J | 1 |
| Ryckewaert, G | 1 |
| Rouaix, N | 1 |
| Jissendi, P | 1 |
| Dujardin, K | 1 |
| Ravasi, L | 1 |
| Hopes, L | 1 |
| Firdaus, W | 1 |
| Sablonnière, B | 1 |
| Strubi-Vuillaume, I | 1 |
| Zahr, N | 1 |
| Destée, A | 1 |
| Corvol, JC | 1 |
| Pöltl, D | 1 |
| Leist, M | 1 |
| Rose, C | 1 |
| Marchetti, P | 1 |
| Chaisri, U | 1 |
| Wichaiyo, S | 1 |
| Hemstapat, W | 1 |
| Song, D | 1 |
| Zhao, L | 2 |
| Li, Y | 1 |
| Hadziahmetovic, M | 2 |
| Schmidt, PJ | 1 |
| Racie, T | 1 |
| Westerman, M | 1 |
| Fitzgerald, K | 1 |
| Butler, JS | 1 |
| Fleming, MD | 1 |
| Wang, C | 1 |
| Xu, X | 1 |
| Jinnah, HA | 1 |
| Wodzinska, J | 1 |
| Iacovelli, J | 1 |
| Wolkow, N | 1 |
| Krajacic, P | 1 |
| Weissberger, AC | 1 |
| Lee, MK | 1 |
| Connor, J | 1 |
| Giasson, B | 1 |
| Harris, ZL | 1 |
| Bose, C | 1 |
| Megyesi, JK | 1 |
| Shah, SV | 1 |
| Hiatt, KM | 1 |
| Hall, KA | 1 |
| Karaduta, O | 1 |
| Swaminathan, S | 1 |
| Casu, C | 1 |
| Aghajan, M | 1 |
| Oikonomidou, PR | 1 |
| Guo, S | 1 |
| Monia, BP | 1 |
| Rivella, S | 1 |
| Garringer, HJ | 1 |
| Irimia, JM | 1 |
| Li, W | 1 |
| Goodwin, CB | 1 |
| Richine, B | 1 |
| Acton, A | 1 |
| Chan, RJ | 1 |
| Peacock, M | 1 |
| Muhoberac, BB | 1 |
| Ghetti, B | 1 |
| Vidal, R | 1 |
| Sangartit, W | 1 |
| Pakdeechote, P | 1 |
| Kukongviriyapan, V | 1 |
| Donpunha, W | 1 |
| Shibahara, S | 1 |
| Kukongviriyapan, U | 1 |
| Prasanthi, JR | 1 |
| Schrag, M | 1 |
| Dasari, B | 1 |
| Marwarha, G | 1 |
| Dickson, A | 1 |
| Kirsch, WM | 1 |
| Ghribi, O | 1 |
| Mohammadpour, M | 1 |
| Behjati, M | 1 |
| Sadeghi, A | 1 |
| Fassihi, A | 1 |
| Otto-Duessel, M | 1 |
| Gonzalez, I | 1 |
| Aguilar, MI | 1 |
| Shimada, H | 1 |
| Nick, H | 1 |
| Nelson, M | 1 |
| Moats, R | 1 |
| Gorman, N | 1 |
| Zaharia, A | 1 |
| Trask, HS | 1 |
| Szakacs, JG | 1 |
| Jacobs, NJ | 1 |
| Jacobs, JM | 1 |
| Balestra, D | 1 |
| Sinclair, JF | 1 |
| Sinclair, PR | 1 |
| Ablin, J | 1 |
| Shalev, O | 1 |
| Okon, E | 1 |
| Karmeli, F | 1 |
| Rachmilewitz, D | 1 |
| Berkovitch, M | 1 |
| Livne, A | 1 |
| Lushkov, G | 1 |
| Segal, M | 1 |
| Talmor, C | 1 |
| Bentur, Y | 1 |
| Klein, J | 1 |
| Koren, G | 1 |
| Moridani, MY | 1 |
| O'Brien, PJ | 1 |
| Czachor, JD | 1 |
| Cherian, MG | 1 |
| Koropatnick, J | 1 |
| Hershko, C | 1 |
| Link, G | 1 |
| Konijn, AM | 1 |
| Huerta, M | 1 |
| Rosenmann, E | 1 |
| Reinus, C | 1 |
| Florence, A | 1 |
| Ward, RJ | 1 |
| Peters, TJ | 1 |
| Crichton, RR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of the Iron Chelator Deferiprone on Iron Overload in the Brain in Parkinson's Disease[NCT00943748] | Phase 2/Phase 3 | 40 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for deferiprone and Disease Models, Animal
| Article | Year |
|---|---|
Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis?
Topics: Adult; Amyotrophic Lateral Sclerosis; Animals; Deferiprone; Disease Models, Animal; Dose-Response Re | 2018 |
Targeting chelatable iron as a therapeutic modality in Parkinson's disease.
Topics: Animals; Cell Line; Combined Modality Therapy; Deferiprone; Disease Models, Animal; Double-Blind Met | 2014 |
40 other studies available for deferiprone and Disease Models, Animal
| Article | Year |
|---|---|
Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Behavior, Animal; Binding Sites; Ce | 2020 |
Therapeutic potential of iron modulating drugs in a mouse model of multiple system atrophy.
Topics: alpha-Synuclein; Animals; Brain; Cerebellum; Ceruloplasmin; Copper; Deferiprone; Disease Models, Ani | 2021 |
Novel Antidepressant-Like Properties of the Iron Chelator Deferiprone in a Mouse Model of Depression.
Topics: Animals; Antidepressive Agents; Deferiprone; Depression; Disease Models, Animal; Iron; Iron Chelatin | 2022 |
Pathologically high intraocular pressure disturbs normal iron homeostasis and leads to retinal ganglion cell ferroptosis in glaucoma.
Topics: Animals; Deferiprone; Disease Models, Animal; Ferroptosis; Glaucoma; Homeostasis; Humans; Intraocula | 2023 |
Deferiprone and efonidipine mitigated iron-overload induced neurotoxicity in wild-type and thalassemic mice.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, T-Type; Deferiprone; Dihydropyridines; Disease | 2019 |
Oral administration of the iron chelator deferiprone protects against loss of retinal ganglion cells in a mouse model of glaucoma.
Topics: Administration, Oral; Animals; Deferiprone; Disease Models, Animal; Female; Glaucoma; Iron Chelating | 2020 |
Action of iron chelator on intramyocardial hemorrhage and cardiac remodeling following acute myocardial infarction.
Topics: Animals; Cardiotonic Agents; Deferiprone; Disease Models, Animal; Female; Hemorrhage; Iron Chelating | 2020 |
The
Topics: Animals; Cell Survival; Cells, Cultured; Deferiprone; Disease Models, Animal; Genes, Reporter; Glauc | 2020 |
Effectiveness of deferiprone-loaded nanocarrier in experimentally induced rhabdomyolysis: A dose-comparison study.
Topics: Animals; Deferiprone; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Carriers; Iron | 2020 |
Iron chelation rescues hemolytic anemia and skin photosensitivity in congenital erythropoietic porphyria.
Topics: 5-Aminolevulinate Synthetase; Adult; Anemia, Hemolytic; Animals; Cell Line; Cell Line, Tumor; CRISPR | 2020 |
The Iron Chelator Deferiprone Improves the Phenotype in a Mouse Model of Tauopathy.
Topics: Animals; Deferiprone; Disease Models, Animal; Female; Iron; Iron Chelating Agents; Male; Maze Learni | 2020 |
Prevention of adhesions post-abdominal surgery: Assessing the safety and efficacy of Chitogel with Deferiprone in a rat model.
Topics: Abdomen; Animals; Cecum; Chitosan; Deferiprone; Disease Models, Animal; Enterostomy; Gels; Kaolin; P | 2021 |
SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of β-thalassaemia.
Topics: Acetylgalactosamine; Animals; beta-Thalassemia; Deferiprone; Disease Models, Animal; Drug Therapy, C | 2021 |
Deferiprone and Gallium-Protoporphyrin Have the Capacity to Potentiate the Activity of Antibiotics in
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Bacterial Load; Biofilms; Caenorhabditis el | 2017 |
Renal iron accumulation occurs in lupus nephritis and iron chelation delays the onset of albuminuria.
Topics: Albuminuria; Animals; Deferiprone; Disease Models, Animal; Iron; Iron Chelating Agents; Iron-Binding | 2017 |
Mechanism Underlying the Effectiveness of Deferiprone in Alleviating Parkinson's Disease Symptoms.
Topics: Animals; Deferiprone; Disease Models, Animal; Dopamine; Iron; Iron Chelating Agents; Oxidative Stres | 2018 |
Iron Restriction to Clinical Isolates of Candida albicans by the Novel Chelator DIBI Inhibits Growth and Increases Sensitivity to Azoles
Topics: Animals; Antifungal Agents; Azoles; Candida; Candida albicans; Deferiprone; Deferoxamine; Disease Mo | 2018 |
Iron chelator deferiprone rescues memory deficits, hippocampal BDNF levels and antioxidant defenses in an experimental model of memory impairment.
Topics: Animals; Antioxidants; Brain-Derived Neurotrophic Factor; Deferiprone; Disease Models, Animal; Femal | 2018 |
MRI imaging and histopathological study of brain iron overload of β-thalassemic mice.
Topics: Animals; beta-Thalassemia; Brain; Chelating Agents; Computer Graphics; Deferiprone; Disease Models, | 2019 |
Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Case-Control Studies; Ceruloplasmin; De | 2013 |
Deferiprone and idebenone rescue frataxin depletion phenotypes in a Drosophila model of Friedreich's ataxia.
Topics: Aconitate Hydratase; Animals; Antioxidants; Deferiprone; Disease Models, Animal; Drosophila; Frataxi | 2013 |
Treatment of mercury vapor toxicity by combining deferasirox and deferiprone in rats.
Topics: Animals; Benzoates; Chelating Agents; Deferasirox; Deferiprone; Disease Models, Animal; Drug Therapy | 2013 |
Iron distribution and histopathological characterization of the liver and heart of β-thalassemic mice with parenteral iron overload: Effects of deferoxamine and deferiprone.
Topics: Animals; beta-Globins; beta-Thalassemia; Deferiprone; Deferoxamine; Disease Models, Animal; Female; | 2014 |
The oral iron chelator deferiprone protects against systemic iron overload-induced retinal degeneration in hepcidin knockout mice.
Topics: Administration, Oral; Animals; Deferiprone; Disease Models, Animal; Electroretinography; Ferritins; | 2014 |
Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia.
Topics: Administration, Oral; Animals; beta-Thalassemia; Combined Modality Therapy; Deferiprone; Disease Mod | 2015 |
Cp/Heph mutant mice have iron-induced neurodegeneration diminished by deferiprone.
Topics: Animals; Brain; Ceruloplasmin; Deferiprone; Disease Models, Animal; Iron; Iron Chelating Agents; Mem | 2015 |
Evidence Suggesting a Role of Iron in a Mouse Model of Nephrogenic Systemic Fibrosis.
Topics: Animals; Contrast Media; Deferiprone; Disease Models, Animal; Gadolinium; Gadolinium DTPA; Humans; I | 2015 |
Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia.
Topics: Animals; beta-Thalassemia; Deferiprone; Disease Models, Animal; Erythropoiesis; Iron Chelating Agent | 2016 |
Effect of Systemic Iron Overload and a Chelation Therapy in a Mouse Model of the Neurodegenerative Disease Hereditary Ferritinopathy.
Topics: Animals; Apoferritins; Cell Survival; Cells, Cultured; Chelation Therapy; Deferiprone; Disease Model | 2016 |
Tetrahydrocurcumin in combination with deferiprone attenuates hypertension, vascular dysfunction, baroreflex dysfunction, and oxidative stress in iron-overloaded mice.
Topics: Administration, Oral; Animals; Baroreflex; Curcumin; Deferiprone; Disease Models, Animal; Drug Thera | 2016 |
Deferiprone reduces amyloid-β and tau phosphorylation levels but not reactive oxygen species generation in hippocampus of rabbits fed a cholesterol-enriched diet.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Analysis of Variance; Animals; Aspartic Acid Endopeptidase | 2012 |
Wound healing by topical application of antioxidant iron chelators: kojic acid and deferiprone.
Topics: Administration, Topical; Animals; Antioxidants; Deferiprone; Disease Models, Animal; Drug Therapy, C | 2013 |
Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil.
Topics: Animals; Benzoates; Deferasirox; Deferiprone; Disease Models, Animal; Female; Gerbillinae; Heart; Ir | 2006 |
Effect of an oral iron chelator or iron-deficient diets on uroporphyria in a murine model of porphyria cutanea tarda.
Topics: Animals; Deferiprone; Disease Models, Animal; Iron Chelating Agents; Iron Deficiencies; Liver; Male; | 2007 |
Deferiprone, an oral iron chelator, ameliorates experimental colitis and gastric ulceration in rats.
Topics: Acetates; Administration, Oral; Animals; Colitis; Deferiprone; Disease Models, Animal; Gastric Mucos | 1999 |
The efficacy of oral deferiprone in acute iron poisoning.
Topics: Acute Disease; Administration, Oral; Animals; Biological Availability; Deferiprone; Disease Models, | 2000 |
Iron complexes of deferiprone and dietary plant catechols as cytoprotective superoxide radical scavengers(1).
Topics: Animals; Antioxidants; Catechols; Copper; Deferiprone; Disease Models, Animal; Free Radical Scavenge | 2001 |
Reduction of copper and metallothionein in toxic milk mice by tetrathiomolybdate, but not deferiprone.
Topics: Animals; Copper; Deferiprone; Disease Models, Animal; Hepatolenticular Degeneration; Metallothionein | 2002 |
The iron-loaded gerbil model revisited: effects of deferoxamine and deferiprone treatment.
Topics: Animals; Deferiprone; Deferoxamine; Disease Models, Animal; Female; Gerbillinae; Iron Chelating Agen | 2002 |
Studies of in vivo iron mobilization by chelators in the ferrocene-loaded rat.
Topics: Animals; Brain; Deferiprone; Deferoxamine; Disease Models, Animal; Ferrous Compounds; Heart; Hemochr | 1992 |